Forty Seven, Inc.
We are a clinical-stage immuno-oncology company focused on developing novel checkpoint therapies to activate macrophages in the fight against cancer.
$14.00 - $16.00
MORGAN STANLEY, CREDIT SUISSE, CANACCORD GENUITY, BTIG, OPPENHEIMER & CO.
To view the prospectus for Forty Seven, Inc. IPO, or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253